Display options
Share it on

Am J Nucl Med Mol Imaging. 2013;3(1):85-96. Epub 2013 Jan 05.

Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake.

American journal of nuclear medicine and molecular imaging

David M Schuster, Pooneh A Taleghani, Peter T Nieh, Viraj A Master, Rianot Amzat, Bital Savir-Baruch, Raghuveer K Halkar, Tim Fox, Adeboye O Osunkoya, Carlos S Moreno, Jonathon A Nye, Weiping Yu, Baowei Fei, Zhibo Wang, Zhengjia Chen, Mark M Goodman


  1. Department of Radiology and Imaging Sciences, Emory University Atlanta, GA, USA.

PMID: 23342303 PMCID: PMC3545368


Anti-1-amino-3-[(18)F] fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) is a synthetic amino acid positron emission tomography (PET) radiotracer with utility in the detection of recurrent prostate carcinoma. The aim of this study is to correlate uptake of anti-3-[(18)F] FACBC with histology of prostatectomy specimens in patients undergoing radical prostatectomy and to determine if uptake correlates to markers of tumor aggressiveness such as Gleason score. Ten patients with prostate carcinoma pre-radical prostatectomy underwent 45 minute dynamic PET-CT of the pelvis after IV injection of 347.8 ± 81.4 MBq anti-3-[(18)F] FACBC. Each prostate was co-registered to a separately acquired MR, divided into 12 sextants, and analyzed visually for abnormal focal uptake at 4, 16, 28, and 40 min post-injection by a single reader blinded to histology. SUVmax per sextant and total sextant activity (TSA) was also calculated. Histology and Gleason scores were similarly recorded by a urologic pathologist blinded to imaging. Imaging and histologic analysis were then compared. In addition, 3 representative sextants from each prostate were chosen based on highest, lowest and median SUVmax for immunohistochemical (IHC) analysis of Ki67, synaptophysin, P504s, chromogranin A, P53, androgen receptor, and prostein. 79 sextants had malignancy and 41 were benign. Highest combined sensitivity and specificity was at 28 min by visual analysis; 81.3% and 50.0% respectively. SUVmax was significantly higher (p<0.05) for malignant sextants (5.1±2.6 at 4 min; 4.5±1.6 at 16 min; 4.0±1.3 at 28 min; 3.8±1.0 at 40 min) compared to non-malignant sextants (4.0±1.9 at 4 min; 3.5±0.8 at 16 min; 3.4±0.9 at 28 min; 3.3±0.9 at 40 min), though there was overlap of activity between malignant and non-malignant sextants. SUVmax also significantly correlated (p<0.05) with Gleason score at all time points (r=0.28 at 4 min; r=0.42 at 16 min; r=0.46 at 28 min; r=0.48 at 40 min). There was no significant correlation of anti-3-[(18)F] FACBC SUVmax with Ki-67 or other IHC markers. Since there was no distinct separation between malignant and non-malignant sextants or between Gleason score levels, we believe that anti-3-[(18)F] FACBC PET should not be used alone for radiation therapy planning but may be useful to guide biopsy to the most aggressive lesion.

Keywords: Positron emission tomography (PET); anti-3-[18F] FACBC; prostate carcinoma


  1. Med Res Rev. 2012 Jul;32(4):868-905 - PubMed
  2. J Nucl Med. 2011 May;52(5):822-9 - PubMed
  3. J Nucl Med. 2007 Jan;48(1):56-63 - PubMed
  4. Clin Nucl Med. 2008 Apr;33(4):308-10 - PubMed
  5. IEEE Trans Med Imaging. 2003 Jan;22(1):120-8 - PubMed
  6. J Nucl Med. 2005 Oct;46(10):1642-9 - PubMed
  7. J Nucl Med. 2011 Jan;52(1):81-9 - PubMed
  8. CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29 - PubMed
  9. PET Clin. 2009 Apr 1;4(2):135-8 - PubMed
  10. Semin Nucl Med. 2004 Oct;34(4):274-92 - PubMed
  11. Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):668-73 - PubMed
  12. Nucl Med Biol. 1997 May;24(4):319-25 - PubMed
  13. Clin Nucl Med. 2009 May;34(5):279-84 - PubMed
  14. Anticancer Res. 2003 Jul-Aug;23(4):3413-8 - PubMed
  15. Eur J Nucl Med Mol Imaging. 2008 May;35(5):976-83 - PubMed
  16. Nucl Med Biol. 2012 Jan;39(1):109-19 - PubMed
  17. J Nucl Med. 2012 Apr;53(4):538-45 - PubMed
  18. Appl Radiat Isot. 2003 Jun;58(6):657-66 - PubMed
  19. Amino Acids. 2010 Jun;39(1):11-27 - PubMed
  20. Acta Oncol. 2002;41(5):425-9 - PubMed
  21. J Nucl Med. 2007 Jan;48(1):46-55 - PubMed
  22. J Urol. 2009 Dec;182(6):2702-7 - PubMed
  23. Eur J Nucl Med Mol Imaging. 2002 Nov;29(11):1492-5 - PubMed
  24. J Urol. 2005 Jan;173(1):66-9; discussion 69 - PubMed
  25. In Vivo. 2005 Sep-Oct;19(5):911-20 - PubMed
  26. Cancer J. 2005 Nov-Dec;11(6):437-41 - PubMed
  27. J Nucl Med. 2006 Aug;47(8):1249-54 - PubMed
  28. Pathol Int. 2009 Jan;59(1):7-18 - PubMed
  29. J Cell Biochem Suppl. 1992;16H:74-7 - PubMed
  30. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):742-8 - PubMed
  31. Radiology. 2011 Jun;259(3):852-61 - PubMed
  32. Semin Cancer Biol. 2005 Aug;15(4):254-66 - PubMed
  33. Urology. 2000 Nov 1;56(5):823-7 - PubMed
  34. BJU Int. 2012 Mar;109(5):660-4 - PubMed

Publication Types

Grant support